Clinical Trial Update: Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS [Phase 2, Phase 3]

View source ↗

Summary

The Phase 2/3 clinical trial of BDB-001 in patients with severe COVID-19 and ALI/ARDS was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Injury
• Respiratory Distress Syndrome

Drugs mentioned

• BDB-001

Snippet

Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd | Conditions: COVID-19 Pneumonia | Phase 2, Phase 3 | Status: TERMINATED